Five Under Five Under 5: Top Oncology Videos for the Week of 1/4

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These brief videos are designed for busy oncologists, offering expert insights on breaking news, regulatory updates, practice-changing data from medical meetings, and other key topics in oncology.

FDA approval of subcutaneous amivantamab for EGFR‑mutant NSCLC — Joshua K. Sabari, MD
Joshua K. Sabari of NYU Grossman School of Medicine reviewed the FDA approval of subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for EGFR‑mutant non–small cell lung cancer. Data from the phase 1 PALOMA and phase 3 PALOMA‑3 trials showed pharmacokinetic noninferiority to IV amivantamab, with fewer infusion‑related reactions and simplified clinic workflows, offering a more patient‑friendly option without compromising efficacy.

FDA approval of enfortumab vedotin plus pembrolizumab for cisplatin‑ineligible MIBC — Christof Vulsteke, MD, PhD
Christof Vulsteke discussed the FDA approval of enfortumab vedotin‑ejfv (Padcev) combined with pembrolizumab (Keytruda) for cisplatin‑ineligible muscle‑invasive bladder cancer. The decision was supported by the phase 3 KEYNOTE‑905 trial and addresses a major unmet need for patients unable to receive cisplatin. The combination leverages complementary mechanisms and should be considered for eligible patients, with additional follow‑up needed to define benefit beyond cisplatin‑ineligible populations.

Three‑year data for perioperative toripalimab plus chemotherapy in gastric and GEJ cancer — Shuqiang Yuan, MD, PhD
Shuqiang Yuan reviewed 3‑year follow‑up from the phase 2 NEOSUMMIT‑01 trial of perioperative toripalimab‑tpzi (Loqtorzi) with chemotherapy in locally advanced gastric and gastroesophageal junction cancer. Results presented at ASCO GI showed significant improvements in event‑free survival and overall survival versus chemotherapy alone, including in mismatch repair–proficient tumors, and a meaningful reduction in peritoneal metastasis with the toripalimab combination.

Real‑world performance of SKY92 gene expression profiling in multiple myeloma — Noa Biran, MD
Noa Biran summarized findings from the prospective PROMMIS study evaluating the SKY92 gene expression assay for risk stratification in multiple myeloma. About 30% of patients had discordant risk classification between SKY92 and International Myeloma Society criteria. Patients deemed high risk by SKY92 experienced poor outcomes regardless of IMS‑defined risk, suggesting SKY92 identifies aggressive disease biology not consistently captured by conventional stratification.

Key data for zanidatamab‑based combinations in HER2‑positive gastroesophageal adenocarcinoma — Elena Elimova, MD
Elena Elimova highlighted early‑phase data showing promising activity and a manageable safety profile for zanidatamab‑based combinations in HER2‑positive gastroesophageal adenocarcinoma. Combinations with chemotherapy and immune checkpoint inhibitors have demonstrated encouraging response signals, and larger randomized trials are under way to confirm benefit and define optimal regimens.